Olpruva (Sodium Phenylbutyrate) Patent Expiration, LOE Window & CMS Spending

Olpruva (Sodium Phenylbutyrate) by Acer Therapeutics: FDA Orange Book LOE 2036-10-17, 3 AB generics, $488K 2024 CMS Part D & Medicaid spend, and $57,029 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcer Therapeutics
FDA Application & PathwayN214860 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-10-17
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$488K
2024 Medicare Part D Spend$488K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($57,029 intro WAC)